Updated 12:29am 30 May 2012

Powered by Google

GlaxoSmithKline counts the cost of legal fight

THE UK's largest pharmaceutical company today said the cost of settling legal disputes over controversial diabetes drug Avandia will hit a record £2.2bn.Read

GlaxoSmithKline

Region in the running for GlaxoSmithKline jobs

PHARMACEUTICAL giant GlaxoSmithKline is considering building a new North East plant as part of plans to invest £500m in manufacturing which could create around 1,000 jobs.Read

Swine flu fears help GSK sales surge 13%

PHARMACEUTICALS giant GlaxoSmithKline revealed a further boost from last year’s swine flu crisis as it said H1N1 treatments helped first- quarter sales surge 13%.Read

Swine flu jab gives GlaxoSmithKline £1bn boost

SOARING global demand for swine flu vaccinations is expected to give drug giant GlaxoSmithKline a £1bn sales boost in the final three months of the year.Read

Swine flu to give £1.5bn boost to drug companies

SALES of the swine flu vaccine are expected to deliver a £1.5bn boost to Britain's biggest drug companies in the final three months of 2009, according to reports.Read

On watch this week for turning point in recession

OFFICIAL UK output figures for the second quarter will provide the economic highlight next week, and GlaxoSmithKline is due to report back on trading.Read

GSK in £750m Chroma deal

PHARMACEUTICALS giant GlaxoSmithKline has signed a deal worth up to £750m with Chroma Therapeutics Ltd to develop new drugs.Read

GSK to buy stake in generic drug maker

PHARMACEUTICAL company GlaxoSmithKline is to buy a 16% stake in Aspen Pharmacare, Africa’s biggest generic drug manufacturer.Read

Tamiflu

Drugs companies set to benefit from flu outbreak

THE threat of a pandemic triggered by a new flu strain that has killed more than 100 people in Mexico is expected to be a windfall for some makers of drugs and vaccines.Read

GlaxoSmithKline at Barnard Castle

Fresh fears for jobs as GSK eyes up cuts

THERE are fresh concerns for North East jobs after it was reported drugs giant GlaxoSmithKline is set to wield the axe again when it announces its full-year results later this week.Read

Glaxo SmithKline

Glaxo to axe 200 jobs at its North East factory

DRUGS giant GlaxoSmith- Kline yesterday revealed that 200 jobs will go at its County Durham factory, but pledged to invest £17m in the site next year.Read

Glaxo to shed 200 jobs

DRUGS giant GlaxoSmithKline has confirmed it is axing 200 jobs at its County Durham factory but pledged to invest £17m in the site next year.Read

Bitter pill for workers at GSK factory

UP to 100 jobs are expected to go at the North East base of one of the UK’s largest private companies as it looks to make cutbacks in the light of falling sales and profits.Read

Historic week in more ways than one

TO say that the events of last week were momentous would hardly overstate the case.Read

300 jobs to go as drugs giant tightens belt

DRUGS giant GlaxoSmithKline has started a voluntary redundancy programme at its County Durham site as part of a global shake-up which has already seen 300 jobs go at its plant in Cumbria.Read

Drugs giant profits rise

Drugs giant AstraZeneca today upped its earnings guidance for the year after reporting a better-than-expected hike in third quarter profits.Read

GSK up despite slide in profits

THE FTSE 100 index closed the day 188.84 points lower at 4040.89.Read

GSK drop 42p despite deal news

IN the regional portfolio, pharmaceutical firm GlaxoSmithKline announced it has struck a deal with Bristol Myers Squibb to buy its portfolio of mature medicines in Egypt.Read

Question mark over jobs at GSK

A QUESTION mark is hanging over the future of jobs at drugs firm GlaxoSmithKline’s Barnard Castle factory as part of cost-cutting which has already cut 300 jobs in the North.Read

Profits rise puts GSK in focus

AFTER spending some of the day in positive territory, the UK stock market retreated into the red and ended the week’s opening session down 40 points at 5312.6.Read